Laura Rosiñol
University of Barcelona
429 Papers
1.5K Citations
Laura Rosiñol is an academic researcher from University of Barcelona. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 55, co-authored 308 publications. Previous affiliations of Laura Rosiñol include National and Kapodistrian University of Athens & Hospital Universitario La Paz.
Chat about Author
Papers
CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
Aina Oliver-Caldés,Luis Gerardo Rodríguez-Lobato,Verónica González-Calle,Natalia Tovar,Valentin Cabañas,Paula Rodriguez-Otero,Juan Luis Reguera,Marta Español-Rego,Beatriz Martín-Antonio,Aintzane Zabaleta,Marta Lasa,Susana Inogés,Ascensión López-Díaz de Cerio,Bruno Paiva,Sara Varea,Joaquín Sáez-Peñataro,Manel Juan,Laura Rosiñol,Felipe Prosper,José M. Moraleda,Alvaro Urbano-Ispizua,Mariona Pascal,Maria-Victoria Mateos,Carlos Fernández de Larrea +23 more
1
POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)
N. W. van de Donk,Philippe Moreau,A. Garfall,Manisha Bhutani,Albert Oriol,Ajay K. Nooka,Thomas Martin,Laura Rosiñol,Maria-Victoria Mateos,Nizar J. Bahlis,Rakesh Popat,Britta Besemer,Joaquín Martínez Lopez,Amrita Krishnan,Michel Delforge,D. Trancucci,Raluca I. Verona,Tara Stephenson,Katherine Chastain,Surbhi Sidana +19 more
1
BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma
Tania Díaz,Vanina Rodriguez,Ester Lozano,E. Valls,Marcos Calderón,Laura Rosiñol,A. Martinez,Natalia Tovar,Patricia Pérez-Galán,Antonio Postigo,J. Bladé,Gaël Roué,C. Fernández de Larrea +12 more
TL;DR: In this paper, the effect of combining a BET bromodomain inhibitor with a lenalidomide and dexamethasone (Len/Dex) regimen was evaluated in patients with multiple myeloma.
1
Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)
C. Guerrero,R. Termini,Juan José Garcés,María José Calasanz,Rafael Rios,Elena Cabezudo,Laura Rosiñol,Bargay Joan,Albert Pérez-Montaña,A. O. Rocafiguera,Valentin Cabanas Perianes,Maria-Josefa Najera,Esther Gonzalez Garcia,Enrique M. Ocio,Anna Sureda Balari,Felipe de Arriba,M. T. Hernández Garcia,Antonio Garcia,Joaquin Martinez-Lopez,María Jesús Blanchard,Marta Sonia González Pérez,Rebeca Méndez Iglesias,A. Orfao,M. Mateos,J. J. Lahuerta Palacios,Joan Bladé,Jesús F. San Miguel,Maria-Teresa Cedena,Noemi Puig,Bruno Paiva +29 more
TL;DR: Studying genetic drivers of tumor egress, CTCs were found to closely resemble BM tumor cells (88% concordance at copy number [CNA] and somatic mutational [SNV] level) and, along with the IMWG 20/2/20 model, had independent prognostic value.
1
Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup
Antonio Palumbo,Meletios A. Dimopoulos,P. Moreau,Wee Joo Chng,Hartmut Goldschmidt,Roman Hájek,Thierry Facon,Heinz Ludwig,Ludek Pour,Ruben Niesvizky,Albert Oriol,Laura Rosiñol,Aleksandr Suvorov,Gianluca Gaidano,Tomas Pika,Katja Weisel,V. Goranova-Marinova,Heidi H. Gillenwater,Nehal Mohamed,Shibao Feng,Douglas E. Joshua +20 more
- 03 Dec 2015
TL;DR: A preplanned subgroup analysis of efficacy and safety outcomes of the ENDEAVOR study according to age found PFS was improved with Kd vs Vd within each age subgroup, and ORRs in each age group were also higher in the Kd arm compared with the Vd arm in each subgroup.
1